Ito Hitoshi, Yaegashi Hiroshi, Okada Yoshiyuki, Shimada Takafumi, Yamaoka Toshihide, Okubo Kazutoshi, Sakamoto Takashi, Mizokami Atsushi
Department of Radiation Oncology, Kyoto Katsura Hospital, Kyoto, Japan.
Department of Integrative Cancer Therapy and Urology, Kanazawa University,Graduate School of Medical Science, Kanazawa, Japan.
Cancer Diagn Progn. 2021 Jul 3;1(4):323-330. doi: 10.21873/cdp.10043. eCollection 2021 Sep-Oct.
BACKGROUND/AIM: Radium-223 therapy prolongs overall survival in castration-resistant prostate cancer (CRPC) patients with bone metastasis. Patients who are unable to complete six courses of radium-223 therapy reportedly have a poor prognosis. This study aimed to develop a risk score using the discontinuation factors of the above therapy modality.
Seventy patients who received radium-223 therapy for metastatic CRPC at two Japanese Institutions were evaluated. Univariate and multivariate analyses were performed to identify the discontinuation factors and determine the risk scores.
The median survival time was 24.3 and 9.5 months in patients who did and did not complete the therapy, respectively. Multivariate analysis revealed haemoglobin and prostate-specific antigen as key factors. A risk score was developed using these factors, and patients were stratified into three groups. The discontinuation rate and survival after radium-223 therapy were significantly different.
Our risk score may help evaluate the suitability of radium-223 in CRPC patients.
背景/目的：镭-223疗法可延长去势抵抗性前列腺癌（CRPC）骨转移患者的总生存期。据报道，无法完成六个疗程镭-223治疗的患者预后较差。本研究旨在利用上述治疗方式的中断因素制定一个风险评分。
对日本两家机构中70例接受镭-223治疗的转移性CRPC患者进行评估。进行单因素和多因素分析以确定中断因素并确定风险评分。
完成和未完成治疗的患者中位生存时间分别为24.3个月和9.5个月。多因素分析显示血红蛋白和前列腺特异性抗原是关键因素。利用这些因素制定了一个风险评分，并将患者分为三组。镭-223治疗后的中断率和生存率有显著差异。
我们的风险评分可能有助于评估镭-223在CRPC患者中的适用性。
